A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer

Cancer

Volumn 117, Issue 3, 2011, Pages 526-533

  Picus, Joel ^a   Halabi, Susan ^b,c   Kelly, W Kevin ^d   Vogelzang, Nicholas J ^e   Whang, Young E ^f   Kaplan, Ellen B ^b   Stadler, Walter M ^g   Small, Eric J ^h  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE CANCER CENTER   (United States)

^e NEVADA CANCER INSTITUTE   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bevacizumab; castrate resistant prostate cancer; docetaxel; progression free survival

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE SODIUM; PROSTATE SPECIFIC ANTIGEN;

ACIDOSIS; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APHASIA; ARTICLE; BONE PAIN; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASTRATION; CEREBROVASCULAR ACCIDENT; COLITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EMBOLISM; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; ILEUS; INFECTION; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; LEUKOCYTE COUNT; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELENA; MESENTERIC VEIN THROMBOSIS; METABOLIC ACIDOSIS; MOOD DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEINURIA; SIDE EFFECT; STOMATITIS; SYNCOPE; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

EID: 79251516754     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25421     Document Type: Article

References (20)

1. Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer. 1990; 66: 1039-1044.
2. Tannock I, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1488-1490.
3. Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520.
4. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26: 242-245.
5. Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003; 98: 2592-2598.
6. Dawson NA, Halabi S, Ou SS, et al. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone-refractory prostate cancer: results of Cancer and Leukemia Group B trial 90004. Clin Genitourin Cancer. 2008; 6: 110-116.
7. Ferrara N, Davis-Smyth T., The biology of vascular endothelial growth factor. Endocrinology. 1997; 18: 1-22.
8. Ferrara N., Role of vascular endothelial growth factor in regulation of angiogenesis. Kidney Int. 1999; 56: 794-814.
9. Pallares J, Rojo F, Iriarte J, et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol. 2006; 21: 857-865.
10. Ferrer FA, Miller LJ, Andrawis RJ., Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of FEGG by human prostate cancer cells. J Urol. 1997; 157: 2329-2333.
11. Duque J, Loughlin K, Adam R., Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999; 45: 523-527.
12. Bok R, Halabi S, Fei D, et al. VEGF and bFGF urine levels as predictors of outcome in hormone refractory prostate cancer patients: a CALGB study. Cancer Res. 2001; 61: 2533-2536.
13. George D, Halabi S, Shepard T, et al. Prognostic significance of plasma vascular endothelial growth factor (VEGF) levels in patients with hormone refractory prostate cancer: a CALGB study. Clin Cancer Res. 2001; 7: 1932-1936.
14. Reese D, Fratesi P, Corry M., A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhu-MAb VEGF) for the treatment of androgen-independent prostate cancer. Prostate. 2001; 3: 65-70.
15. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 3461-3467.
16. Kaplan EL, Meier P., Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
17. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol. 2001; 19: 2509-2516.
18. Scher HI, Halabi S, Tannock I, et al. Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.
19. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99: 1232-1239.
20. Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ., Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma. Cancer. 2004; 101: 2755-2759.